Literature DB >> 10600487

The regulation of caveolin expression and localization by serum and heparin in vascular smooth muscle cells.

T E Peterson1, L S Kleppe, N M Caplice, S Pan, C S Mueske, R D Simari.   

Abstract

Caveolae have been implicated in growth factor receptor and G-protein coupled receptor signaling in vascular cells. It has been postulated that caveolin, the structural protein of caveolae, may act as a general tyrosine kinase inhibitor by binding and inhibiting signaling molecules involved in the activation of the MAP kinase proliferation cascade. Using an in vitro model of VSMC proliferation, we found that serum stimulation caused a dose dependent decrease in both caveolin-1 and caveolin-2 protein levels in human coronary artery smooth muscle cells. Heparin, an inhibitor of VSMC proliferation, inhibited the serum-induced loss of caveolin-1 and caveolin-2. In addition, heparin caused an increase in both caveolin-1 and caveolin-2 localization to caveolae-enriched sucrose gradient membrane fractions when compared to serum alone. Taken together, caveolin may play an important role in the regulation of VSMC proliferation and heparin and serum have opposing effects on caveolin expression and localization in VSMC. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600487     DOI: 10.1006/bbrc.1999.1738

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats.

Authors:  Atul Arya; Harlokesh Naryan Yadav; P L Sharma
Journal:  Mol Cell Biochem       Date:  2011-04-06       Impact factor: 3.396

2.  Heparin responses in vascular smooth muscle cells involve cGMP-dependent protein kinase (PKG).

Authors:  Albert C Gilotti; Wutigri Nimlamool; Raymond Pugh; Joshua B Slee; Trista C Barthol; Elizabeth A Miller; Linda J Lowe-Krentz
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.